47 results about "Pharmacologic action" patented technology

A computer-implemented system for personalized health optimization constructs a confidence-weighted personal health knowledge graph (PHKG) from heterogeneous data, including wearable sensors, medical devices, lab results, medication logs, and conversational inputs. A multi-stage causal-inference stack identifies modifiable drivers of outcomes using layered methods (e.g., MI, GAM, Neural Granger, DAG-GNN), and simulates candidate interventions. A recommendation engine ranks lifestyle or pharmacologic actions using a benefit-to-friction score, selecting a personalized intervention aligned with user readiness and clinical safety constraints. Interventions may include a minimum effective dose (MED), optimal level, adaptive low-dose, or behavioral challenge. Optional modules include reinforcement learning for timing adaptation and privacy-preserving on-device inference. The system operates across domains including metabolic, cardiovascular, renal, sleep, stress, and medication response, enabling cross-condition synergy evaluation. The architecture is modular, supports runtime plug-in targets, and adapts in real time with or without continuous clinical oversight, depending on deployment.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The invention belongs to the technical field of organic synthesis. The invention particularly relates to a synthesis method of chiral beta-diaryl ethanol. The physiological activity, the pharmacological action and the material performance of the chiral molecule are directly determined by the spatial configuration of the chiral molecule. Therefore, efficient construction of chiral compounds is always the core research direction of organic synthesis and medicinal chemistry. Wherein the chiral beta-diaryl ethanol is a kind of key intermediates with irreplaceable application value. According to the invention, the Suzuki-Miyaura type asymmetric ring-opening coupling reaction of nickel catalyzed aryl epoxy and aryl boric acid with high stereoselectivity is realized, and the asymmetric ring-opening coupling reaction is used for synthesizing chiral beta-diaryl alcohol compounds. The method is wide in substrate compatibility and raw material source, mild in reaction condition, free of exogenous alkali and convenient to operate. An aryl epoxy compound and arylboronic acid are used as raw materials, diethylene glycol dimethyl ether nickel bromide is used as a catalyst, chiral biimidazoline is used as a ligand, under the promotion of sodium iodide, reaction is performed in an ethanol solvent according to the following reaction formula at the temperature of 50 DEG C for 10 hours, and the chiral beta-diaryl ethanol compound with the high ee value is obtained.

The invention discloses a hypnotic traditional Chinese medicine pillow based on traditional Chinese medicine theory and ergonomics and a traditional Chinese medicine formula in the pillow, and particularly relates to the technical field of hypnotic traditional Chinese medicine pillows.The hypnotic traditional Chinese medicine pillow comprises a pillow inner body and detachable medicine bags, the detachable medicine bags are symmetrically arranged on the left side and the right side of the pillow inner body, and the detachable medicine bags are filled with traditional Chinese medicine mixtures; the traditional Chinese medicine mixture is prepared from the following raw materials in parts by weight: 1 part of rhizoma atractylodis, 1 part of rhizoma acori graminei, 0.5 part of radix angelicae, 1 part of wormwood, 1 part of rhizoma cyperi and 0.2 part of rhizoma kaempferiae. The components complement and cooperate in pharmacological action to jointly enhance the effects of tranquilizing and allaying excitement and improving sleep, the sleeping effect is improved in cooperation with a specific micronization treatment and low-temperature crushing process, and the traditional Chinese medicine sleeping effect is improved through deep integration of the traditional Chinese medicine sleeping theory, ergonomic design and a modern preparation process. The nerve soothing effect of traditional Chinese medicine and cervical vertebra comfortable supporting form a superimposed effect, and multi-dimensional upgrading from a single sleeping function to stable medicine effect, comfortable use and convenient maintenance is achieved.

The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting lycium barbarum glycopeptide metabolites in rat plasma and tissues based on non-targeted metabonomics. According to the method, after rat lycium barbarum glycopeptides are administered through intragastric administration, blood, liver, intestine, lung and brain tissue samples after administration are collected. A UPLC-Q-TOF-MS (Ultra Performance Liquid Chromatography-Quadrupole Time of Flight Mass Spectrometry) analysis method is combined with a statistical analysis method comprising principal component analysis (PCA) and orthogonal-partial least squares discriminant analysis (OPLS-DA) to carry out in-vivo metabonomics analysis on the wolfberry glycopeptide. Then, based on a human metabolome database (HMDB), lycium barbarum glycopeptide differential metabolite is searched, so that the pharmacological action mechanism of the lycium barbarum glycopeptide is clarified from the perspective of metabolism, and a foundation is laid for deep research and development of the medicinal value of the lycium barbarum glycopeptide in future.

The invention relates to the field of biological medicine, in particular to vortioxetine and application of pharmaceutically acceptable salts, solvates, crystal forms and prodrugs of vortioxetine to preparation of drugs for preventing or treating pathogenic fungal infection. The application reveals that the antidepressant vortioxetine (vortioxetine) and hydrobromide thereof (vortioxetine. HBr) which are sold on the market have measurable in-vitro inhibitory activity on various clinical common pathogenic fungi for the first time, so that the pharmacological action spectrum of the compound is expanded, and a new candidate direction is provided for research and development of antifungal drugs; the application not only overcomes the defects of existing antifungal drugs in the aspects of drug resistance, biological membranes and safety, but also opens up a brand new application direction of mental small molecule drugs in the anti-infection field, and has remarkable technical innovation, social value and industrial popularization prospect. The application also provides a theoretical basis for establishing a'multi-modal micromolecular antifungal library ', and can promote the development of pharmacological mechanism research and fungal infection precise treatment.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

The application discloses application of a Fructus Mume pill in preparation of a medicine for treating diabetic encephalopathy, and finds that there is a clear correlation between the Fructus Mume pill and the diabetic encephalopathy. Research results show that the Fructus Mume pill can improve the abnormal metabolic state of a diabetic model mouse, reduce learning and memory dysfunction and cognitive impairment under a diabetic state, and has a good prevention and treatment effect on the diabetic encephalopathy. The application clearly defines the pharmacological effect of the Fructus Mume pill in preventing and treating the diabetic encephalopathy and a possible action mechanism, and provides an experimental basis for TCM intervention on the diabetic encephalopathy. The application provides a new train of thought for research and development of a medicine related to the diabetic encephalopathy, and has a good application prospect.

The present invention provides diazo compounds having anti-trypanosomal activity, with less or no side-effects. The diazo compounds are structural analogue of quinapyramine and possess characteristics necessary for the targeted pharmacologic action of anti trypanosomosis, with reduced cytotoxicity. The compounds were found to have less cytotoxicity, and identical or better anti- parasitemia effect as compared to conventional quinapyramine sulfate.

The application belongs to the technical field of biological medicine, and particularly relates to application of calcium chelator BAPTA and a pharmaceutical composition. The calcium chelator BAPTA delays aging of lung fibroblasts and lung tissues by eliminating calcium accumulation in lung fibroblasts, reducing accumulation of reactive oxygen species ROS (ROS) in lung fibroblasts, DNA damage, and release of inflammatory factors. The calcium chelator BAPTA ultimately realizes the function of treating pulmonary fibrosis by inhibiting weight loss, lung tissue inflammatory cell infiltration, lung collagen deposition, and expression of fibrosis markers. The application provides a new drug source for delaying aging of lung fibroblasts and lung tissues and studying occurrence and development of pulmonary fibrosis. The drug is safe and reliable, has strong pharmacological action, small side effects, and definite curative effect.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating lung-spleen qi deficiency type allergic rhinitis and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials: 5 to 40 parts of radix astragali seu hedysari, 3 to 25 parts of radix rehmanniae, 3 to 20 parts of rhizoma atractylodis macrocephalae, 2 to 10 parts of herba ephedrae, 3 to 20 parts of rhizoma seu radix notopterygii, 3 to 15 parts of radix saposhnikoviae, 3 to 20 parts of cortex moutan, 3 to 15 parts of radix paeoniae rubra, 5 to 25 parts of radix cynanchi paniculati, 3 to 20 parts of bombyx batryticatus, 3 to 20 parts of cortex cercis chinensis, 3 to 20 parts of ramulus mori and 10 to 30 parts of oyster. The prescription is accurate in syndrome type and treats both symptoms and root causes. The comprehensive intervention system aiming at the complicated pathological network of allergic rhinitis is constructed through multi-target collaborative intervention and fusion of multiple pharmacological actions of enriching yin and tonifying qi, dispersing wind pathogen, activating blood and clearing damp, dispelling wind and dredging collaterals and the like. And the medicines are natural, so that the safety basis is good.

The invention relates to a crystal form of a bipyrimidine compound as well as a preparation method and application thereof. In particular, the present invention relates to a crystalline form I of 4 '-cyclopropyl-5, 6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2, 5 '-bipyrimidinyl]-4-amine, a crystalline form II of 4'-cyclopropyl-5, 6 '-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2 An X-ray powder diffraction pattern of the compound comprises characteristic peaks at diffraction angles (2 theta) of 6.378 + / -0.2 degrees, 9.521 + / -0.2 degrees, 15.721 + / -0.2 degrees, 16.379 + / -0.2 degrees, 16.981 + / -0.2 degrees, 17.560 + / -0.2 degrees, 19.080 + / -0.2 degrees and 22.200 + / -0.2 degrees. The crystal form I is high in stability, high in solubility, high in blood concentration, high in bioavailability and excellent in pharmacological action, so that the crystal form I is suitable for pharmaceutical preparations.

The invention discloses temperature control type dragon's blood cataplasm as well as a preparation method and application thereof, and belongs to the technical field of medical instruments and traditional Chinese medicine external preparations. The cataplasm is of a layered composite structure and comprises a backing layer, a temperature control heating layer, a heat insulation temperature control layer, a cataplasm matrix layer containing a dragon's blood extract and an anti-sticking layer. Through cooperation of the heating layer material and the breathable temperature control material, the application temperature can be accurately controlled to be 40-50 DEG C and lasts for 2-4 hours, controllable low-temperature thermal therapy and the pharmacological action of the dragon's blood are organically combined, and synergistic interaction of thermal therapy and medical therapy is achieved. The product can remarkably promote hematoma absorption and relieve swelling and pain, is safe and convenient to use, is particularly suitable for treatment of subacute stages such as post-trauma subcutaneous hematoma, post-arterial paracentesis subcutaneous hematoma and soft tissue injury, and has a wide clinical application prospect.

The present application belongs to the technical field of biological medicine, and particularly relates to a method for predicting the in-vitro immunogenicity of biological drugs based on co-culture of dendritic cells and T cells. The present application constructs an in-vitro immunogenicity evaluation method with immature dendritic cells as the core. By limiting the dendritic cell differentiation time, not introducing any maturation stimulating factors, and removing free drug molecules after antigen treatment and then co-culturing with T cells, the T cell activation is mainly derived from the antigen presentation process itself, thereby effectively reducing the interference of drug pharmacological action or non-specific immune activation on the detection results. At the same time, the present application discards the traditional detection method relying on T cell proliferation or cytokine release, and adopts the early activation state of T cells as the evaluation index, thereby reducing the experimental complexity, shortening the experimental period, and solving the technical problem that the specificity is insufficient and the experimental period is too long to be considered in the existing in-vitro immunogenicity evaluation method.

The invention relates to the technical field of biology, in particular to application of Erythritol in preparation of a medicine for treating diabetic retinopathy. According to the application, angiogenesis in the diabetic retinopathy process is relieved by a method of inhibiting ferroptosis through the active metabolite Erythrotol, and from the perspective of metabonomics, it is found for the first time that the metabolite Erythrotol inhibits ferroptosis by regulating the activity of ACSL4, the angiogenesis is relieved, and the DR process is delayed. The Erythritol is convenient to extract, high in stability, remarkable in pharmacological action, small in molecular weight and high in stability, has the characteristics of good bioavailability, effective antioxidant activity, easiness in clinical transformation and the like, and is expected to become an ideal choice for treating many diseases. Based on the various advantages, new treatment thinking and targets can be provided for diagnosis and treatment of DR.

The toxicity prediction method comprises the following steps: integrating and analyzing various chemical structure characteristics, pharmacological action data and existing toxicity experiment results of various antibiotics, and applying multiple linear regression which is a powerful statistical tool to predict the toxicity of the recycled water containing the antibiotics, so as to predict the toxicity of the recycled water containing the antibiotics. And a prediction model capable of accurately reflecting the complex relationship between the toxicity of the antibiotics and the chemical structure of the antibiotics is constructed. The model not only can provide quantitative prediction on the toxicity of the antibiotics, but also can reveal key factors influencing the toxicity, so that valuable reference information is provided for research and development personnel.

This invention provides a traditional Chinese and Tibetan medicine composition with functions of improving microcirculation and promoting diuresis and removing dampness. Animal experiments revealed that, in terms of pharmacological activities such as improving microcirculation and promoting diuresis and removing dampness, the removal of ephedra significantly reduced the aforementioned pharmacological activities in the standard formula of Wuwei Ganlu. However, the addition of ginger, cinnamon twig, and hot spring water significantly enhanced the overall pharmacological effects of the formula, specifically by promoting microcirculation, reducing the incidence of drug-induced renal edema, increasing glomerular filtration rate, and improving the relative expression level of the aqp3a gene related to aquaporin 3 (AQP3).

A forest therapy program prescription method and system are provided. The forest therapy program prescription system receives a pre-bio-signal measurement value from a sensor attached to a user, receives user input information from the user, analyzes the pre-bio-signal measurement value so as to calculate, on the basis of data stored in a storage unit, a first score numerically representing the necessity of each of a plurality of plant fragrances having pharmacological efficacy, analyzes the user input information so as to calculate, on the basis of the data stored in the storage unit, a second score numerically representing the necessity of each of the plurality of plant fragrances having pharmacological efficacy, and provides, on the basis of the first score and the second score, a forest therapy program prescription that provides plant fragrances.

The application discloses application of calyculostero in preparation of blood sugar reducing drugs, and belongs to the technical field of pharmacological action of calyculostero. Experimental results show that the calyculostero can inhibit the activity of pancreatic alpha-amylase (IC50 is 4.34+ / -1.10 ug / mL) in a dose-dependent manner, reduce postprandial blood sugar, and improve sugar tolerance, reduce fasting blood sugar, improve total cholesterol and triglyceride levels, and reduce histopathological changes of liver, pancreas and kidney in long-term intervention, and has no obvious hepatotoxicity. The calyculostero can be used alone or together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and is used for reducing blood sugar or treating diabetes, and the dosage form includes oral preparations, injections and the like. The application provides a new natural medicine selection for drug treatment of diabetes.

Through virtual screening based on molecular docking, molecular dynamics simulation, free energy calculation and experimental verification, it is found for the first time that benfotiamine can efficiently antagonize P2Y14R, and the IC50 value of benfotiamine reaches 0.31 nM. Experimental results show that benfotiamine can significantly relieve inflammatory reactions of a DSS-induced mouse colitis model and an MSU-induced gouty arthritis model, and the action mechanism of benfotiamine is closely related to inhibition of activation of NLRP3 inflammasomes. Benfotiamine is used as a vitamin B1 derivative clinically applied for a long time and has good safety and tolerance. The invention provides a brand new pharmacological action target and indication direction, realizes new use of old medicines, is beneficial to shortening the research and development period of medicines and reducing the development cost, and has important application prospects and economic and social values in the field of treatment of inflammatory diseases.

The invention provides a preparation process and application of a traditional Chinese medicine patch for inducing diuresis to alleviate edema, and belongs to the technical field of medicine patches. Comprising the following steps: S1, treating raw materials; s2, powdering and sieving; s3, adding auxiliary materials, and stirring to prepare a medicine ball; s4, extruding; s5, strip making; s6, pelleting; s7, preparing an application; and S8, packaging and storing. The therapeutic effect is synergistically achieved through the stimulation effect and pharmacological action of the medicine on acupuncture points, the spleen and stomach transportation and transformation functions can be enhanced, the water-dampness metabolism capacity of the body can be enhanced, water delivery and distribution can be adjusted to improve the urination function, the mode of oral medicine is effectively replaced, and infection to the urinary system of a patient is avoided.

The invention belongs to the technical field of medicines, and discloses application of a compound BA-7 in preparation of medicines for treating and preventing cerebral infarction. Specifically, the invention discloses a pharmacological action of the p-hydroxybenzyl substituted tryptophan compound for treating cerebral infarction. Experimental results prove that the compound BA-7 has the effects of obviously reducing the volume of cerebral infarction after acute cerebral ischemia of rats and improving neural behavior defects, and is expected to become a medicine for treating inflammation-related diseases.

The application discloses a method for extracting effective active components from Radix Cinnamomi, which comprises the following steps: firstly, extracting Radix Cinnamomi with ethanol; then, extracting the ethanol extract with petroleum ether, ethyl acetate and n-butanol respectively; detecting whether there are obvious peaks by TLC; collecting different fractions by elution and washing of the ethyl acetate extract with obvious peaks through an alumina column; and obtaining target products by crystallization and drying treatment of the fractions, and then identifying the target products by infrared, hydrogen spectrum, carbon spectrum, mass spectrum and ultraviolet combined detection, wherein the target products are identified as monomer compounds of berberine hydrochloride, jatrorrhizine hydrochloride and palmatine hydrochloride. The method can further separate monomer compounds of Radix Cinnamomi, can better control the quality standard of Radix Cinnamomi, can lay a good foundation for further research on the pharmacological action of Radix Cinnamomi, and can lay a foundation for the research on new drugs with antitumor, antioxidant, immunoregulatory activity and anti-inflammatory effects.

The invention discloses application of radix codonopsis and fructus corni dizziness-clearing paste in preparation of a medicine for treating endolymphatic dropsy and the medicine, and relates to the technical field of traditional Chinese medicines. The invention further discloses application of the radix codonopsis and fructus corni dizziness-clearing paste to preparation of a medicine for treating endolymphatic dropsy. According to the application disclosed by the invention, the radix codonopsis and fructus corni dizziness clearing paste is applied to treating the endolymphatic dropsy for the first time, and a 9.4 T ultrahigh field intensity MRI technology is innovatively adopted, so that the pharmacological action of the preparation for remarkably relieving the endolymphatic dropsy is intuitively and quantitatively proved on a living animal model, and objective and reliable direct evidence is provided for the curative effect of the preparation. The invention not only opens up a brand new medical application for the radix codonopsis and fructus corni dizziness-clearing paste, but also provides an objective, direct and scientific visual verification means for the curative effect of the radix codonopsis and fructus corni dizziness-clearing paste, and overcomes the defects of lack of targeted drugs and clear mechanism research in the prior art. And a traditional Chinese medicine solution with a clear and reliable curative effect mechanism is provided for the treatment of the endolymphatic dropsy.

This invention discloses an orally disintegrating film formulation of BPC-157 sodium salt for treating acute alcohol poisoning and its preparation method. It relates to the field of acute alcohol poisoning treatment technology. The orally disintegrating film formulation comprises, by weight percentage: 0.1-5% BPC-157 sodium salt, 40-70% film-forming material, 5-15% plasticizer, 0.1-15% disintegrant, 0.1-15% sweetener, 0.1-10% salivary stimulant, and 1-5% other excipients. This invention prepares an orally disintegrating film formulation of BPC-157 sodium salt, utilizing its rapid dissolution characteristics and the pharmacological effects of BPC-157, providing a new option for treating acute alcohol poisoning. This formulation has advantages such as rapid onset of action, high bioavailability, and few side effects, and is expected to become an effective drug for treating acute alcohol poisoning.

The invention discloses a compound for improving hepatic fatty degeneration, and relates to the technical field of biological medicines, and the compound is selected from 4-acetaminobutyric acid or pharmaceutically acceptable salts thereof; liver fatty degeneration is liver lipid accumulation caused by metabolism-related fatty liver disease (MAFLD); the liver fatty degeneration is improved by reducing the content of triglyceride (TG) in liver cells; the medicine is suitable for treating metabolism-related steatohepatitis (MASH), obesity-related chronic inflammatory diseases or liver injury related to metabolic syndrome; the pharmacological action of the 4-acetaminobutyric acid in the aspect of improving hepatic fatty degeneration can effectively reduce the content of triglyceride in hepatic cells and effectively relieve hepatic lipid accumulation caused by metabolism-related fatty liver diseases (MAFLD), and the compound is high in safety, free of obvious cytotoxicity under the effective concentration, simple and convenient in synthesis method, controllable in cost and suitable for industrial production. The pharmaceutical composition has various dosage forms.

This invention provides a method and system for big data analysis and processing of drug incompatibilities, relating to the field of pharmaceutical data processing technology. The method includes acquiring a drug dataset containing drug identifiers and pharmacological targets; performing topological adaptive hierarchical clustering based on multidimensional semantic mapping of targets; constructing local compatibility subgraphs at each level and extracting topological invariants as feature codes; calculating the topological similarity of adjacent level subgraphs using graph convolution operators to construct a compatibility risk propagation tensor field; conducting multi-scale risk signal propagation along the tensor field; and implementing adaptive attenuation and proportional allocation based on eigenvalue spectra to achieve cross-level risk aggregation and form a global risk assessment tensor; and outputting the drug combination incompatibility determination results through manifold dimensionality reduction projection.

The application discloses a construction method and application of a carfentanyl mouse withdrawal model, and belongs to the field of biological medicine technology and animal model construction; carfentanyl is injected into the mouse, and the injection period is 6 days; 2 injections are injected every day in the first 5 days, and the interval between the injections is 12 hours; the injection dose of each injection on the nth day is n times of the injection dose of each injection on the first day; one injection is injected on the sixth day, and the injection dose is the same as the injection dose of each injection on the fifth day; the withdrawal is carried out after the injection is completed to obtain the carfentanyl mouse withdrawal model; the model of the application has fewer drug administration days, fewer drug administration times and uses less medicine, compared with the model constructed in the foregoing research; the model of the application has fewer drug administration days, fewer drug administration times and uses less medicine, and provides more economical, more efficient and more comprehensive reference evidence for the addiction and harmfulness of carfentanyl; the model can be widely applied to related researches such as pharmacological action evaluation or drug treatment of carfentanyl and similar new psychoactive substances.

The application discloses a naringin high-efficiency extraction process optimization and multi-dimensional biological activity research method based on a low eutectic solvent. Through systematic screening of 11 kinds of low eutectic solvents (Deep Eutectic Solvents, DESs) and 2 kinds of traditional organic solvents on the extraction efficiency of naringin, it is determined that the low eutectic solvent composed of tetraethyl ammonium bromide and 1,2-propanediol is the optimal solvent, the extraction process parameters are optimized through single factor experiment and response surface method, and the optimal extraction conditions of naringin are obtained. The extracted naringin is subjected to antioxidant and antibacterial activity detection, the MoGAPI method is used for life cycle assessment of the extraction process, and through network pharmacology and molecular docking technology, the potential action target, signal pathway and molecular binding mechanism of naringin in treating gastric cancer are explored. The method is high in extraction efficiency, green in environmental protection and safe in operation, and further systematically clarifies the multi-dimensional biological activity and potential pharmacological action of naringin, thereby providing reliable process and theoretical support for the green industrialized production and subsequent development and application of naringin.

The application discloses a natural medicine compound for treating Alzheimer's disease and application thereof, and the compound comprises the following components: 3-6 parts of Gastrodia elata, 3-6 parts of Polygala, 3-6 parts of Radix Notoginseng, 3-6 parts of Uncaria, 9-15 parts of Radix Rehmanniae Preparata, 9-15 parts of Radix Anemarrhenae, 6-10 parts of Fructus Schisandrae, 6-9 parts of Fried Semen Ziziphi Preparatum, 2-5 parts of Chuanxiong Rhizoma, 3-6 parts of Radix Paeoniae Alba, 9-15 parts of Radix et Rhizoma Bambusae, 1-5 parts of Carthamus, 6-10 parts of Atractylodes, 6-9 parts of Poria, 9-15 parts of Ophiophagus, 3-9 parts of Angelica, 9-15 parts of Radix et Rhizoma Ginseng, 2-5 parts of Salvia, and 2-5 parts of Radix Glycyrrhizae. The application further discloses a pharmacological action mechanism of the Tianqi granules for treating AD and application of the Tianqi granules in preventing and / or treating Alzheimer's disease. The application is a natural medicine, contains multiple active components, has scientific dosage, no side effect, and provides a new effective natural medicine compound for treating AD, and plays a significant role in benefiting a large number of patients and benefiting human health.